Cannabinoid oral spray - Aphria/Medlab

Drug Profile

Cannabinoid oral spray - Aphria/Medlab

Latest Information Update: 29 Aug 2016

Price : $50

At a glance

  • Originator Aphria; Medlab
  • Developer Medlab
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Pain

Most Recent Events

  • 22 Aug 2016 Early research in Pain in Australia (PO)
  • 22 Aug 2016 Medlab plans a phase I/II study in Pain in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top